Literature DB >> 3117702

Why is Pseudomonas the colonizer and why does it persist?

R Ramphal1, S Vishwanath.   

Abstract

Pseudomonas aeruginosa is currently the major cause of morbidity and mortality in cystic fibrosis. Studies to understand why this particular organism is a problem and why host defenses fail to clear it, are beginning to provide some answers. Implicit in any working hypothesis are the prerequisites that: (i) P. aeruginosa should have a tropism for the respiratory tract; (ii) there should be a physical clearance defect; and (iii) there should be an acquired immune clearance defect. Studies from many laboratories support these contentions. This organism exhibits its tropism by adhering to tracheal cells and to tracheobronchial mucins by means of pili or the mucoid exopolysacharide of mucoid strains. The receptors on both cells and mucins contain sialic acid as the dominant sugar moiety. Many factors contribute to its persistence, chief among which is the failure of phagocytic defenses caused by microbial or host enzymes and even by mucins which inhibit the opsonophagocytosis of P. aeruginosa. Injury to the mucociliary system, again caused by microbial or host factors, is also a prominent factor in the persistence of P. aeruginosa. We hypothesize that this organism is the dominant pathogen because of the existence of receptors in the respiratory tract for it and that it persists because bacteria in stagnant mucus cannot be cleared physically or immunologically. We are doubtful that conventional vaccination approaches will yield a solution to this problem.

Entities:  

Mesh:

Year:  1987        PMID: 3117702     DOI: 10.1007/bf01644139

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  31 in total

1.  The flora of the respiratory tract of patients with cystic fibrosis of the pancreas.

Authors:  N N HUANG; E L VAN LOON; K T SHENG
Journal:  J Pediatr       Date:  1961-10       Impact factor: 4.406

2.  Action of certain carbohydrates on the reaction of Eberthella typhosa with antibody O.

Authors:  L OLITZKI; M SHELUBSKY; E EFRATI
Journal:  Proc Soc Exp Biol Med       Date:  1947-02

3.  Bronchopulmonary symptoms in primary ciliary dyskinesia. A clinical study of 27 patients.

Authors:  M Pedersen; G Stafanger
Journal:  Eur J Respir Dis Suppl       Date:  1983

4.  Pseudomonas aeruginosa mucoid strain. Its significance in adult chest diseases.

Authors:  M Rivera; M B Nicotra
Journal:  Am Rev Respir Dis       Date:  1982-11

5.  The lung in cystic fibrosis. A quantitative study including prevalence of pathologic findings among different age groups.

Authors:  C W Bedrossian; S D Greenberg; D B Singer; J J Hansen; H S Rosenberg
Journal:  Hum Pathol       Date:  1976-03       Impact factor: 3.466

6.  Proteins of the cystic fibrosis respiratory tract. Fragmented immunoglobulin G opsonic antibody causing defective opsonophagocytosis.

Authors:  R B Fick; G P Naegel; S U Squier; R E Wood; J B Gee; H Y Reynolds
Journal:  J Clin Invest       Date:  1984-07       Impact factor: 14.808

7.  Pseudomonas aeruginosa adhesins for tracheobronchial mucin.

Authors:  R Ramphal; C Guay; G B Pier
Journal:  Infect Immun       Date:  1987-03       Impact factor: 3.441

8.  Adherence of Pseudomonas aeruginosa to tracheal cells injured by influenza infection or by endotracheal intubation.

Authors:  R Ramphal; P M Small; J W Shands; W Fischlschweiger; P A Small
Journal:  Infect Immun       Date:  1980-02       Impact factor: 3.441

9.  Similarity of the tracheobronchial mucous glands and epithelium in infants with and without cystic fibrosis.

Authors:  E H Oppenheimer
Journal:  Hum Pathol       Date:  1981-01       Impact factor: 3.466

10.  Evidence for mucins and sialic acid as receptors for Pseudomonas aeruginosa in the lower respiratory tract.

Authors:  R Ramphal; M Pyle
Journal:  Infect Immun       Date:  1983-07       Impact factor: 3.441

View more
  10 in total

Review 1.  Pseudomonas biofilm matrix composition and niche biology.

Authors:  Ethan E Mann; Daniel J Wozniak
Journal:  FEMS Microbiol Rev       Date:  2012-01-23       Impact factor: 16.408

2.  Treatment of infections in patients with cystic fibrosis.

Authors:  M I Marks
Journal:  Infection       Date:  1987       Impact factor: 3.553

3.  Qualitative and quantitative microbiological analysis of sputa of 102 patients with cystic fibrosis.

Authors:  A Bauernfeind; R M Bertele; K Harms; G Hörl; R Jungwirth; C Petermüller; B Przyklenk; C Weisslein-Pfister
Journal:  Infection       Date:  1987 Jul-Aug       Impact factor: 3.553

4.  Treatment of pseudomonas aeruginosa colonisation in cystic fibrosis.

Authors:  G Steinkamp; B Tümmler; R Malottke; H von der Hardt
Journal:  Arch Dis Child       Date:  1989-07       Impact factor: 3.791

5.  In vitro study of the bronchial mucosa during Pseudomonas aeruginosa infection.

Authors:  S Philippon; H J Streckert; K Morgenroth
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

Review 6.  Microbiology of airway disease in patients with cystic fibrosis.

Authors:  P H Gilligan
Journal:  Clin Microbiol Rev       Date:  1991-01       Impact factor: 26.132

7.  Cytotoxicity of Pseudomonas aeruginosa internal lectin PA-I to respiratory epithelial cells in primary culture.

Authors:  O Bajolet-Laudinat; S Girod-de Bentzmann; J M Tournier; C Madoulet; M C Plotkowski; C Chippaux; E Puchelle
Journal:  Infect Immun       Date:  1994-10       Impact factor: 3.441

8.  Binding of nonmucoid Pseudomonas aeruginosa to normal human intestinal mucin and respiratory mucin from patients with cystic fibrosis.

Authors:  U Sajjan; J Reisman; P Doig; R T Irvin; G Forstner; J Forstner
Journal:  J Clin Invest       Date:  1992-02       Impact factor: 14.808

9.  Human immune response to Pseudomonas aeruginosa mucoid exopolysaccharide (alginate) vaccine.

Authors:  G B Pier; D DesJardin; M Grout; C Garner; S E Bennett; G Pekoe; S A Fuller; M O Thornton; W S Harkonen; H C Miller
Journal:  Infect Immun       Date:  1994-09       Impact factor: 3.441

Review 10.  Bacterial infections in patients with primary ciliary dyskinesia: Comparison with cystic fibrosis.

Authors:  Christiaan Dm Wijers; James F Chmiel; Benjamin M Gaston
Journal:  Chron Respir Dis       Date:  2017-03-06       Impact factor: 2.444

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.